import { createFileRoute, Link } from "@tanstack/react-router";
import { ArrowLeft, CheckCircle2, FileText, Globe2, ShieldCheck } from "lucide-react";
import { CTABand } from "@/components/site/Bits";

const imgArticle = "/assets/brain/eu_mdr_market_1786306179767.png";

export const Route = createFileRoute("/insights/regulation-eu-2024-1860-mdr-ivdr-transition")({
  head: () => ({
    meta: [
      { title: "Regulation EU 2024/1860 MDR Transition | NKB Regovanta" },
      {
        name: "description",
        content: "Strategic implications of extended legacy device deadlines, mandatory supply interruption notifications, and IVD timeline relief.",
      },
      { property: "og:title", content: "Regulation EU 2024/1860 MDR Transition | NKB Regovanta" },
      {
        property: "og:description",
        content: "Strategic implications of extended legacy device deadlines, mandatory supply interruption notifications, and IVD timeline relief.",
      },
      { property: "og:url", content: "https://www.nkbregovanta.com/insights/regulation-eu-2024-1860-mdr-ivdr-transition" },
      { property: "og:type", content: "article" },
      { property: "og:image", content: "https://www.nkbregovanta.com/assets/brain/insight_eu_mdr_1786440985783.png" },
      { name: "twitter:card", content: "summary_large_image" },
      { name: "twitter:title", content: "Regulation EU 2024/1860 MDR Transition | NKB Regovanta" },
      { name: "twitter:description", content: "Strategic implications of extended legacy device deadlines, mandatory supply interruption notifications, and IVD timeline relief." },
      { name: "twitter:image", content: "https://www.nkbregovanta.com/assets/brain/insight_eu_mdr_1786440985783.png" },
    ],
    links: [
      { rel: "canonical", href: "https://www.nkbregovanta.com/insights/regulation-eu-2024-1860-mdr-ivdr-transition" },
    ],
  }),
  component: ArticlePage,
});

function ArticlePage() {
  return (
    <>
      <script
        type="application/ld+json"
        dangerouslySetInnerHTML={{
          __html: JSON.stringify({
            "@context": "https://schema.org",
            "@type": "BlogPosting",
            "headline": "Regulation (EU) 2024/1860: Transitional Extensions and EUDAMED Rollout Priorities",
            "description": "Strategic implications of extended legacy device deadlines, mandatory supply interruption notifications, and IVD timeline relief.",
            "image": "https://www.nkbregovanta.com/assets/brain/insight_eu_mdr_1786440985783.png",
            "author": {
              "@type": "Organization",
              "name": "NKB Regovanta Solutions Pvt. Ltd.",
              "url": "https://www.nkbregovanta.com"
            },
            "publisher": {
              "@type": "Organization",
              "name": "NKB Regovanta Solutions Pvt. Ltd.",
              "logo": {
                "@type": "ImageObject",
                "url": "https://www.nkbregovanta.com/favicon.png"
              }
            },
            "datePublished": "2026-09-04",
            "mainEntityOfPage": "https://www.nkbregovanta.com/insights/regulation-eu-2024-1860-mdr-ivdr-transition"
          })
        }}
      />

      <article className="bg-white py-16 lg:py-24">
        <div className="mx-auto max-w-4xl px-4 sm:px-6 lg:px-8">
          
          <Link to="/insights" className="inline-flex items-center gap-2 text-sm font-semibold text-navy/70 hover:text-navy transition-colors mb-8">
            <ArrowLeft className="h-4 w-4" /> Back to Insights
          </Link>

          <div className="flex items-center gap-3 mb-6">
            <span className="text-[11px] font-bold uppercase tracking-widest text-[#0b3a96] bg-blue-50 px-3 py-1 rounded-full border border-blue-100">
              EU REGULATORY UPDATES
            </span>
            <span className="text-navy/30 text-sm">•</span>
            <span className="text-sm font-medium text-navy/60">2026-09-04</span>
          </div>

          <h1 className="text-3xl sm:text-4xl lg:text-5xl font-extrabold text-navy leading-tight mb-6">
            Regulation (EU) 2024/1860: Transitional Extensions and EUDAMED Rollout Priorities
          </h1>

          <p className="text-lg sm:text-xl text-blue-900/80 font-medium leading-relaxed mb-10 pb-6 border-b border-gray-100">
            Strategic implications of extended legacy device deadlines, mandatory supply interruption notifications, and IVD timeline relief.
          </p>

          <img 
            src={imgArticle} 
            alt="Regulation (EU) 2024/1860: Transitional Extensions and EUDAMED Rollout Priorities" 
            className="w-full h-[380px] sm:h-[420px] object-cover rounded-xl mb-12 shadow-md border border-gray-100" 
          />

          <div className="prose prose-lg max-w-none text-navy/80 space-y-6 leading-relaxed">
<h2 className="text-2xl sm:text-3xl font-bold text-navy mt-12 mb-6 tracking-tight">Regulation (EU) 2024/1860: Extension of IVDR Transitional Period and New Provisions</h2>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Extension of IVDR Transitional Period</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">The Regulation (EU) 2024/1860, which amends Regulations (EU) 2017/745 (MDR) and (EU) 2017/746 (IVDR), has been published in the Official Journal of the European Union (OJEU). This legislation aims to ensure the continuity of supply for in vitro diagnostic devices on the European market. It also revises provisions related to the mandatory use of EUDAMED for devices that comply with one of the regulations or were placed on the market under previous directives (legacy devices). Additionally, the regulation introduces a requirement for manufacturers and all economic operators in the supply chain to declare any supply disruptions or risks of such disruptions.</p>

<h2 className="text-2xl sm:text-3xl font-bold text-navy mt-12 mb-6 tracking-tight">Looking for Consultant?</h2>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Get CE Mark for Your Medical Devices</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Click here</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Key Points:</p>

<ul className="my-6 space-y-2 list-disc list-inside text-navy/80 bg-slate-50/60 p-5 rounded-xl border border-slate-200/60">
  <li className="leading-relaxed"><span className="text-navy font-medium">Mandatory Reporting of Supply Interruptions: Manufacturers must notify relevant authorities and healthcare providers of any anticipated interruptions or discontinuations in a device’s supply that could impact patient safety.</span></li>
  <li className="leading-relaxed"><span className="text-navy font-medium">Extended Transitional Periods for IVDs: To address delays in Eudamed’s clinical investigation system development and limited notified body capacity, the transition period for certain IVDs has been extended. This extension aims to prevent shortages of critical medical devices.</span></li>
  <li className="leading-relaxed"><span className="text-navy font-medium">Phased Rollout of Eudamed: The European database on medical devices (Eudamed) will be introduced in stages as its electronic systems become operational. This phased approach will minimize disruption for manufacturers and notified bodies.</span></li>
</ul>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Do You Need Help Understanding This New Amendment and Its Details or Support in Implementing the New Regulation?</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">NKB Regovanta is poised to assist manufacturers in navigating the latest regulatory updates introduced by the European Commission. With the extension of compliance deadlines for legacy in vitro diagnostic (IVD) devices and the phased rollout of EUDAMED, our expert consultants will provide comprehensive support to ensure your products meet the updated IVDR requirements. We will help you apply with a designated notified body, secure necessary agreements well in advance, and manage the timely submission of compliance documentation. Additionally, our team will guide you through the new notification requirements to prevent device shortages, ensuring smooth communication with relevant authorities. By partnering with NKB Regovanta, manufacturers can confidently adapt to the new regulatory landscape, maintaining compliance and market access in the European Union.</p>

<h2 className="text-2xl sm:text-3xl font-bold text-navy mt-12 mb-6 tracking-tight">Categories</h2>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">CDSCO Category</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Medical device Manufacturing</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">News/Updates</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">QMS</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Regulatory</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Turnkey Project Management</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">US FDA</p>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Subscribe Newsletter</p>

<h2 className="text-2xl sm:text-3xl font-bold text-navy mt-12 mb-6 tracking-tight">Recent Posts</h2>

<p className="text-base sm:text-lg leading-relaxed text-navy/80 my-5">Predetermined Change Control Plan (PCCP) for SaMD: FDA Requirements</p>
          </div>

          <div className="mt-16 p-8 bg-gradient-to-br from-blue-50/60 to-slate-50 border border-blue-100 rounded-2xl">
            <h3 className="text-2xl font-bold text-navy mb-4">How NKB Regovanta Can Support Your Programme</h3>
            <p className="text-navy/80 leading-relaxed mb-6">
              Our multidisciplinary team of regulatory affairs strategists, former auditors, and quality system engineers partners with medical technology innovators worldwide. We bridge complex regulatory standards with practical, commercial market-access pathways.
            </p>
            <div className="grid sm:grid-cols-2 gap-4">
              <div className="flex items-center gap-3 p-3 bg-white rounded-lg border border-blue-100/60">
                <CheckCircle2 className="h-5 w-5 text-accent shrink-0" />
                <span className="text-sm font-semibold text-navy">Global Regulatory Strategy &amp; Submissions</span>
              </div>
              <div className="flex items-center gap-3 p-3 bg-white rounded-lg border border-blue-100/60">
                <ShieldCheck className="h-5 w-5 text-accent shrink-0" />
                <span className="text-sm font-semibold text-navy">Technical Documentation &amp; GSPR Files</span>
              </div>
              <div className="flex items-center gap-3 p-3 bg-white rounded-lg border border-blue-100/60">
                <FileText className="h-5 w-5 text-accent shrink-0" />
                <span className="text-sm font-semibold text-navy">ISO 13485 &amp; FDA QMSR Implementation</span>
              </div>
              <div className="flex items-center gap-3 p-3 bg-white rounded-lg border border-blue-100/60">
                <Globe2 className="h-5 w-5 text-accent shrink-0" />
                <span className="text-sm font-semibold text-navy">Market Authorization &amp; Authorized Representation</span>
              </div>
            </div>
          </div>
        </div>
      </article>

      <CTABand 
        title="Ready to navigate your medical device regulatory pathway?" 
        description="Speak directly with NKB Regovanta's senior regulatory consultants for clear, practical guidance." 
        action="Schedule a Consultation" 
      />
    </>
  );
}
